|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qian X, Qin J, Pan S, Li X, Pan Y and Ma
S: Maintenance therapy in ovarian cancer with targeted agents
improves PFS and OS: A systematic review and meta-analysis. PLoS
One. 10:e01390262015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen J, Solomides C, Parekh H, Simpkins F
and Simpkins H: Cisplatin resistance in human cervical, ovarian and
lung cancer cells. Cancer Chemother Pharmacol. 75:1217–1227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J and Wu GS: Role of autophagy in
cisplatin resistance in ovarian cancer cells. J Biol Chem.
289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Makin G and Dive C: Apoptosis and cancer
chemotherapy. Trends Cell Biol. 11:S22–S26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaltouki A, Freer M, Mei Y and Weyman CM:
Increased expression of the pro-apoptotic Bcl2 family member PUMA
is required for mitochondrial release of cytochrome C and the
apoptosis associated with skeletal myoblast differentiation.
Apoptosis. 12:2143–2154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott FL, Denault JB, Riedl SJ, Shin H,
Renatus M and Salvesen GS: XIAP inhibits caspase-3 and −7 using two
binding sites: Evolutionarily conserved mechanism of IAPs. EMBO J.
24:645–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zumbrägel FK, Machtens DA, Curth U, Lüder
CG, Reubold TF and Eschenburg S: Survivin does not influence the
anti-apoptotic action of XIAP on caspase-9. Biochem Biophys Res
Commun. 482:530–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Q, Wang H, Chen S, Lan X, Xiao H, Shi
H and Ma Y: Fiber-optic-based micro-probe using hexagonal 1-in-6
fiber configuration for intracellular single-cell pH measurement.
Anal Chem. 87:7171–7179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang
H, Xiao S, Liu Y, Qiu H, Qin L, et al: Reversing drug resistance of
cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J
Clin Exp Med. 8:6687–6701. 2015.PubMed/NCBI
|
|
11
|
Zhao WJ, Deng BY, Wang XM, Miao Y and Wang
JN: XIAP associated factor 1 (XAF1) represses expression of
X-linked inhibitor of apoptosis protein (XIAP) and regulates
invasion, cell cycle, apoptosis, and cisplatin sensitivity of
ovarian carcinoma cells. Asian Pac J Cancer Prev. 16:2453–2458.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mabuchi S, Kawase C, Altomare DA,
Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M,
Klein-Szanto AJ, Schilder RJ, et al: mTOR is a promising
therapeutic target both in cisplatin-sensitive and
cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer
Res. 15:5404–5413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: MiR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feng X, Li L, Jiang H, Jiang K, Jin Y and
Zheng J: Dihydroartemisinin potentiates the anticancer effect of
cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer
cells: Involvement of apoptosis and autophagy. Biochem Biophys Res
Commun. 444:376–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng DJ, Wang J, Zhou JY and Wu GS: Role
of the Akt/mTOR survival pathway in cisplatin resistance in ovarian
cancer cells. Biochem Biophys Res Commun. 394:600–605. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu H, Zhao Y, Mu X, Wu H, Chen L, Liu W,
Mu Y, Liu J and Wei X: A silica-polymer composite nano system for
tumor-targeted imaging and p53 gene therapy of lung cancer. J
Biomater Sci Polym Ed. 26:384–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mabuchi S, Hisamatsu T, Kawase C, Hayashi
M, Sawada K, Mimura K, Takahashi K, Takahashi T, Kurachi H and
Kimura T: The activity of trabectedin as a single agent or in
combination with everolimus for clear cell carcinoma of the ovary.
Clin Cancer Res. 17:4462–4473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Qin Y, Yang C, Zhang H, Li Y, Wu B,
Huang J, Zhou X, Huang B, Yang K and Wu G: Cardamonin induces
ROS-mediated G2/M phase arrest and apoptosis through inhibition of
NF-κB pathway in nasopharyngeal carcinoma. Cell Death Dis.
8:e30242017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Sikka S, Siveen KS, Lee JH, Um
JY, Kumar AP, Chinnathambi A, Alharbi SA, Basappa, Rangappa KS, et
al: Cardamonin represses proliferation, invasion, and causes
apoptosis through the modulation of signal transducer and activator
of transcription 3 pathway in prostate cancer. Apoptosis.
22:158–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shrivastava S, Jeengar MK, Thummuri D,
Koval A, Katanaev VL, Marepally S and Naidu VGM: Cardamonin, a
chalcone, inhibits human triple negative breast cancer cell
invasiveness by downregulation of Wnt/β-catenin signaling cascades
and reversal of epithelial-mesenchymal transition. Biofactors.
43:152–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YJ, Kang KS, Choi KC and Ko H:
Cardamonin induces autophagy and an antiproliferative effect
through JNK activation in human colorectal carcinoma HCT116 cells.
Bioorg Med Chem Lett. 25:2559–2564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu N, Liu J, Zhao X, Yan Z, Jiang B, Wang
L, Cao S, Shi D and Lin X: Cardamonin induces apoptosis by
suppressing STAT3 signaling pathway in glioblastoma stem cells.
Tumour Biol. 36:9667–9676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia D, Tan Y, Liu H, Ooi S, Li L, Wright
K, Bennett S, Addison CL and Wang L: Cardamonin reduces
chemotherapy-enriched breast cancer stem-like cells in vitro and in
vivo. Oncotarget. 7:771–785. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El-Naga RN: Pre-treatment with cardamonin
protects against cisplatin-induced nephrotoxicity in rats: Impact
on NOX-1, inflammation and apoptosis. Toxicol Appl Pharmacol.
274:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Y, Fang Q, Shi D, Niu P, Chen Y and
Deng J: mTOR inhibition of cardamonin on antiproliferation of A549
cells is involved in a FKBP12 independent fashion. Life Sci.
99:44–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niu PG, Zhang YX, Shi DH, Liu Y, Chen YY
and Deng J: Cardamonin inhibits metastasis of lewis lung carcinoma
cells by decreasing mTOR activity. PLoS One. 10:e01277782015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue ZG, Niu PG, Shi DH, Liu Y, Deng J and
Chen YY: Cardamonin inhibits angiogenesis by mTOR downregulation in
SKOV3 cells. Planta Med. 82:70–75. 2016.PubMed/NCBI
|
|
28
|
Mabuchi S, Altomare DA, Cheung M, Zhang L,
Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR:
RAD001 inhibits human ovarian cancer cell proliferation, enhances
cisplatin-induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
González-Martín A, Sánchez-Lorenzo L,
Bratos R, Márquez R and Chiva L: First-line and maintenance therapy
for ovarian cancer: Current status and future directions. Drugs.
74:879–889. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mould T: An overview of current diagnosis
and treatment in ovarian cancer. Int J Gynecol Cancer. 22 Suppl
1:S2–S4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan LP, Chou TH, Ding HY, Chen PR, Chiang
FY, Kuo PL and Liang CH: Apigenin induces apoptosis via tumor
necrosis factor receptor- and Bcl-2-mediated pathway and enhances
susceptibility of head and neck squamous cell carcinoma to
5-fluorouracil and cisplatin. Biochim Biophys Acta. 1820:1081–1091.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tripathi R, Samadder T, Gupta S, Surolia A
and Shaha C: Anticancer activity of a combination of cisplatin and
fisetin in embryonal carcinoma cells and xenograft tumors. Mol
Cancer Ther. 10:255–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Wang Q, Zhang S, Zhang Y and Tao
L: Baicalein increases the cytotoxicity of cisplatin by enhancing
gap junction intercellular communication. Mol Med Rep. 10:515–521.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sankaranarayanan R and Ferlay J: Worldwide
burden of gynaecological cancer: The size of the problem. Best
Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Elias ST, Borges GA, Rêgo DF, E Silva LF,
Avelino S, DE Matos Neto JN, Simeoni LA and Guerra EN: Combined
paclitaxel, cisplatin and fluorouracil therapy enhances ionizing
radiation effects, inhibits migration and induces G0/G1 cell cycle
arrest and apoptosis in oral carcinoma cell lines. Oncol Lett.
10:1721–1727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Li W, Deng W, Gan Y, Wu K and Sun J:
Synergistic anti-proliferative and pro-apoptotic activities of 5F
and cisplatin in human non-small cell lung cancer NCI-H23 cells.
Oncol Lett. 14:5347–5353. 2017.PubMed/NCBI
|
|
37
|
Chen X, Gong L, Ou R, Zheng Z, Chen J, Xie
F, Huang X, Qiu J, Zhang W, Jiang Q, et al: Sequential combination
therapy of ovarian cancer with cisplatin and γ-secretase inhibitor
MK-0752. Gynecol Oncol. 140:537–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Taylor-Harding B, Orsulic S, Karlan BY and
Li AJ: Fluvastatin and cisplatin demonstrate synergistic
cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol.
119:549–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park S, Gwak J, Han SJ and Oh S:
Cardamonin suppresses the proliferation of colon cancer cells by
promoting β-catenin degradation. Biol Pharm Bull. 36:1040–1044.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang H, Zhang Z, Wei X and Dai R:
Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and
enhances cisplatin-induced apoptosis in ovarian cancer cells. J
Ovarian Res. 8:32015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yadav VR, Prasad S and Aggarwal BB:
Cardamonin sensitizes tumour cells to TRAIL through ROS- and
CHOP-mediated up-regulation of death receptors and down-regulation
of survival proteins. Br J Pharmacol. 165:741–753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wangpaichitr M, Wu C, You M, Kuo MT, Feun
L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin
sensitivity through down-regulation of growth and anti-apoptotic
proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aide N, Kinross K, Cullinane C, Roselt P,
Waldeck K, Neels O, Dorow D, McArthur G and Hicks RJ: 18F-FLT PET
as a surrogate marker of drug efficacy during mTOR inhibition by
everolimus in a preclinical cisplatin-resistant ovarian tumor
model. J Nucl Med. 51:1559–1564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hou G, Yang S, Zhou Y, Wang C, Zhao W and
Lu Z: Targeted inhibition of mTOR signaling improves sensitivity of
esophageal squamous cell carcinoma cells to cisplatin. J Immunol
Res. 2014:8457632014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M,
Huang P and Yu D: Inhibition of PI3K/Akt/mTOR signaling pathway
enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line
to cisplatin in vitro. Chin J Cancer Res. 26:564–572.
2014.PubMed/NCBI
|
|
46
|
Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW
and Poon RT: Inhibition of mTOR enhances chemosensitivity in
hepatocellular carcinoma. Cancer Lett. 273:201–209. 2009.
View Article : Google Scholar : PubMed/NCBI
|
